NeuroX1

There are few options for the treatment of neurological and neurodegenerative diseases. The market for neurodegenerative diseases is roughly $52B, while the market for neurological diseases is roughly$ 82B. The market for brain cancer, a traditionally tricky cancer to treat and one that is also applicable to our platform, is several billion as well. If you include all neurological disorders, including rare/orphan diseases, the market is $125.3B by 2030.

Partnerships with several Biopharma companies and academic institutions. Perpetual agreement with academic center/brain bank for various types of diseased brain tissue for our target ID system. Working with two academic groups to explore a handful of neuro-targets with novel compounds. Created 8 BTK1 inhibitors for MS with substantially more favorable (in silico) characteristics than a drug in phase 3 clinical development at Merck KGaA. Partnership with Everlum Bio for pediatric rare diseases and partnership with Entropy Bio to work on neuro-oncology indications.